Geode Capital Management LLC Has $65.77 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Geode Capital Management LLC reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 0.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,562,790 shares of the biopharmaceutical company's stock after selling 8,291 shares during the period. Geode Capital Management LLC owned approximately 1.69% of Ultragenyx Pharmaceutical worth $65,767,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in Ultragenyx Pharmaceutical by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company's stock worth $422,167,000 after acquiring an additional 89,389 shares in the last quarter. Alliancebernstein L.P. boosted its stake in shares of Ultragenyx Pharmaceutical by 5.3% in the fourth quarter. Alliancebernstein L.P. now owns 1,627,932 shares of the biopharmaceutical company's stock valued at $68,487,000 after purchasing an additional 81,667 shares during the period. Pictet Asset Management Holding SA increased its stake in Ultragenyx Pharmaceutical by 125.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 1,173,638 shares of the biopharmaceutical company's stock worth $49,375,000 after buying an additional 653,088 shares during the period. Norges Bank acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter worth $40,463,000. Finally, Eagle Health Investments LP grew its stake in shares of Ultragenyx Pharmaceutical by 11.7% during the fourth quarter. Eagle Health Investments LP now owns 627,600 shares of the biopharmaceutical company's stock valued at $26,403,000 after acquiring an additional 65,900 shares in the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

RARE has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Canaccord Genuity Group raised their price objective on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a report on Tuesday, February 18th. HC Wainwright reaffirmed a "buy" rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Wedbush reissued a "neutral" rating and issued a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Finally, Wells Fargo & Company lifted their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a research report on Friday, December 20th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat, Ultragenyx Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus target price of $92.79.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE traded up $0.71 on Friday, reaching $35.69. The company's stock had a trading volume of 690,760 shares, compared to its average volume of 807,943. The stock has a market cap of $3.35 billion, a PE ratio of -5.63 and a beta of 0.61. Ultragenyx Pharmaceutical Inc. has a twelve month low of $29.59 and a twelve month high of $60.37. The firm's 50 day moving average is $38.57 and its two-hundred day moving average is $44.40.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The firm had revenue of $164.88 million during the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Equities research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Insider Activity

In other news, CEO Emil D. Kakkis sold 73,434 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $3,091,571.40. Following the transaction, the chief executive officer now directly owns 641,731 shares of the company's stock, valued at approximately $27,016,875.10. This represents a 10.27 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the business's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the transaction, the executive vice president now owns 54,991 shares in the company, valued at $2,358,014.08. This trade represents a 5.16 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 124,643 shares of company stock worth $5,256,268. 5.50% of the stock is owned by corporate insiders.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.